You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Colorcon
Medtronic
Moodys
Harvard Business School

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

Patent: 5,393,777

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,393,777
Title: Deferration using anguibactin siderophore
Abstract:Methods for removing ferric iron from aqueous liquids and for performing deferration therapy are disclosed, involving the use of a novel siderophore, termed anguibactin. Anguibactin is isolated from a marine pathogen, Vibrio anguillarum, containing the pMJ1 plasmid. Anguibactin inhibits iron uptake by living cells, wrests iron from vertebrate tissues, removes iron from other siderophores and ferric hydroxide, and removes ferric iron from aqueous solutions, including cell-culture media. For deferration therapy, anguibactin from which bound iron has been removed is administered by dissolving in water or other liquid aqueous pharmaceutical carrier at a dosage typical for other siderophores. Anguibactin is preferably administered intramuscularly or subcutaneously, but can be given intravenously. Oral administration is also possible, particularly if the siderophore is encapsulated in a form allowing it to pass intact through the acidic environment of the stomach but become available for absorption in the intestine. This siderophore has the advantages of low molecular weight, extremely high affinity for ferric iron, and non-use by any known human pathogen. The structure is amenable to immobilization on a solid substrate.
Inventor(s): Crosa; Jorge H. (Tualatin, OR)
Assignee: State of Oregon Acting by and through the State Board of Higher (Eugene, OR)
Application Number:07/614,231
Patent Claims:see list of patent claims

Details for Patent 5,393,777

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck Sharp & Dohme Corp. ZOSTAVAX zoster vaccine live INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION 125123 001 2006-05-25   Start Trial State of Oregon Acting by and through the State Board of Higher (Eugene, OR) 2039-09-23 search
Merck Sharp & Dohme Corp. ZOSTAVAX zoster vaccine live INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION 125123 1 2006-05-25   Start Trial State of Oregon Acting by and through the State Board of Higher (Eugene, OR) 2039-09-23 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Colorcon
Dow
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.